Author: camel

Reno, Nevada--(ACN Newswire via SeaPRwire.com - March 24, 2026) - Scandium Mining Corp. (TSXV: SCY) (OTC PINK: SCYYF) ("Scandium International" or the "Company"), a leader in the advancement of critical mineral resources, is pleased to announce the release of its updated investor presentation, now available to investors and stakeholders. The new presentation can be accessed here: Investor PresentationThe new investor presentation provides updated information on the Nyngan project in New South Wales, Australia, which is now fully shovel-ready. This project is one of only two primary scandium deposits at this advanced stage in the western world, positioning the company at the forefront of the emerging scandium market.Scandium is an essential element in high-performance applications, including aerospace, defense, and clean power generation. Its unique properties-such as exceptional strength-to-weight ratio and improved corrosion resistance when alloyed with aluminum-make it indispensable for the next generation of lightweight, durable materials. As demand grows for advanced technologies and sustainable solutions, scandium's role is increasingly being recognized by innovative manufacturers and governments alike."We're excited to share this comprehensive update on our progress," said Peter Evensen, CEO of Scandium International. "With our mining license now valid over the entire resource, the project is shovel-ready and we are uniquely positioned to supply scandium at scale to industries that are shaping the future."To view the latest presentation and learn more about Scandium Mining's plans, visit: Scandium International Mining CorporationAbout Scandium MiningScandium Mining is dedicated to unlocking the potential of scandium for high-impact industries worldwide. With its shovel-ready primary scandium deposit, the company is committed to responsible development and long-term value creation.For inquiries to Scandium International Mining Corp, please contact: Peter Evensen, President and CEOTel: (775) 355-9500Harry de Jonge (Controller)Tel: (702) 703-0178Email: info@scandiummining.comCautionary Note Regarding Forward-Looking InformationThis news release includes certain information that may be deemed "forward-looking information". Forward-looking information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "continue", "plans" or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, general future plans and objectives for the Company and the Nyngan Scandium Project, are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information.For more information on the Company and the key assumptions, risks and challenges with respect to the forward-looking information discussed herein, and about our business in general, investors should review the Company's most recently filed annual information form, and other continuous disclosure filings which are available at www.scandiummining.com Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289611 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited (‘‘Baguio’’ or the ‘‘Group’’, Stock Code: 01397.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the Year, the Group’s revenue amounted to approximately HK$2,424.6 million, representing a decrease of approximately 6.9% as compared to the same period last year. Profit for the Year amounted to approximately HK$97.1 million, representing an increase of approximately 72.0% as compared to the same period last year. The Board recommends the payment of a final dividend for the Year at HK7.0 cents per share.Business Overview and ProspectsDuring the Year, revenue from cleaning services as the Group’s core business amounted to approximately HK$1,896.5 million, accounting for approximately 78.2% of the Group’s total revenue. The Group’s cleaning services cover various scenarios, including for Government streets, markets, police stations, fire stations, leisure venues, hospitals and clinics. In addition, the Group provides cleaning services for numerous different places such as universities, large exhibition centers, Hong Kong International Airport, housing estates and private institutions.During the Year, the Group successfully awarded a 3-year contract from the Marine Department of the Government for approximately HK$150 million for the provision of “Marine Refuse Cleansing and Disposal Services in the Eastern waters of Hong Kong”. This contract marks a significant milestone for Baguio, as it represents a strategic expansion of its service portfolio from land to sea, further strengthening its leading position in Hong Kong’s integrated environmental services market. Under the contract, Baguio delivers comprehensive marine refuse cleansing and ship refuse collection services in the Eastern waters of Hong Kong starting from 1 October 2025 including, but not limited to: Victoria Harbour, Central, Sheung Wan, Causeway Bay, Tsim Sha Tsui, Yau Ma Tei, Cheung Sha Wan, Shau Kei Wan, Kwun Tong, Sai Kung, Tolo Harbour and Tai Po. Winning this contract signifies strong market recognition of Baguio’s outstanding performance over the past 46 years. The Group will seamlessly extend its professional standards and operational efficiency in land-based waste management to the marine environment, striving to safeguard Hong Kong’s valuable marine ecosystem and present a cleaner, more beautiful Victoria Harbour to both residents and tourists.Waste management and recycling business recorded revenue of approximately HK$277.8 million, accounting for approximately 11.5% of the Group’s total revenue. The gross profit margin of the waste management and recycling business increased from 11.6% for the same period last year to 15.0%, driving the gross profit of this business up by approximately 25.2% to approximately HK$41.9 million, mainly due to the Government’s proactive promotion of recycling and the substantial expansion of the network of recycling spots, including those for food waste, which facilitated public participation and effectively stimulated collection, and the contribution from the green technology business.The Group continued to provide Government-related waste collection services to five districts, serving a population of approximately 1.6 million.In terms of recycling, the Group is contracted by the Environmental Protection Department (“EPD”) of the Government to provide collection services for thousands of recycling spots (including plastics, glass bottles, metals, waste paper and food waste) across Hong Kong. During the Year, the Group provided collection services for recycling bins in public places and schools. Baguio also provides collection services for Recycling Stations of “GREEN@COMMUNITY”, recycling stores and smart recycling machines, and other institutions in Hong Kong. In addition, Baguio also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong, and is one of the market leaders. In addition, during the Year, the Group was successfully awarded two 35-month contracts from the EPD, with a total value of approximately HK$43 million. During the Year, the Group was responsible for operating the “GREEN@Tai Wo” and “GREEN@Po Lam” recycling stores, and collaborated with nearby buildings, organizations, and community stakeholders to establish and operate fixed and mobile recycling spots for waste collection, provide community recycling support to facilitate citizens, and promote and educate the public on waste sorting and recycling in the community to strengthen citizens’ recycling habits.As a leading environmental services provider in Hong Kong, the Group provides integrated environmental management solutions including waste management, smart recycling and professional landscaping services to Kai Tak Sports Park, which hosts major sports events and concerts. With excellent environmental protection technologies and experience in operating large-scale international venues, the Group has fully demonstrated its strength in undertaking large-scale international programmes and delivering high-quality services. During the Year, the Group also provided waste recycling services for various Lunar New Year fairs across Hong Kong Island, Kowloon and the New Territories.Regarding green technology business, the Group won a new contract in relation to the development and supply of a new generation of solar-powered compacting refuse bins to the Government. This innovative product is designed with an auto-sensing inlet and indicator lights, and under its sealed design, it is equipped with devices for ventilation, lighting, and deodorization. Meanwhile, it is equipped with a big data platform and wireless technology to monitor data in real time, enabling effective tracking of the status of waste collection points, strategic deployment of resources, optimization of operational efficiency, and enhanced planning for future initiatives. Furthermore, the solar-powered compacting refuse bins adopt solar panels and rely on renewable energy, which significantly reduces carbon emissions. They can be flexibly deployed in various scenarios, suitable for remote areas where there are no refuse collection points. This product is expected to be gradually launched into the market in 2026.The Group seizes the opportunity of smart city development and has been committed to expanding its market share of smart recycling in recent years. Currently, Baguio’s smart recycling products, such as smart recycling machines, smart food waste recycling machines, and smart balances, have been deployed in different places across Hong Kong, including Government venues and schools, private housing estates, commercial buildings, theme parks, large-scale exhibition venues, and sports stadiums. These products provide the public with convenient recycling services 24 hours a day and help increase Hong Kong’s overall recycling volume.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun converts yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.As for the landscaping business, the Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, Hong Kong Housing Authority, Hospital Authority, Hong Kong Jockey Club, Hong Kong Science Park, the University of Hong Kong, Hong Kong University of Science and Technology, Hong Kong Wetland Park, as well as 33 sports turf venues under the Leisure and Cultural Services Department, etc. During the Year, the Group provided landscaping services for Kai Tak Sports Park, Hong Kong International Airport, Hong Kong-Shenzhen Innovation and Technology Park, Nano Parks, the Tung Chung New Town Extension (West), Hung Shui Kiu/Ha Tsuen New Development Area and the ventilation building at the eastern portal of the Tseung Kwan O – Lam Tin Tunnel.For pest management business, the Group provided pest management services for venues in the Tsuen Wan District during the Year. In addition, the Group provided pest and rodent control services for hospitals, clinics and the headquarters of the Kowloon East, Kowloon Central and Kowloon West Clusters under the Hospital Authority. The Group also continued to provide termite control and monitoring services for 24 temples under the Chinese Temples Committee.The Promotion of Recycling and Proper Disposal of Products (Miscellaneous Amendments) Bill 2025 submitted by the Government was passed by the Legislative Council during the Year. This bill establishes a common legal framework for producer responsibility scheme applicable to different products. Under this framework, the Government plans to submit the producer responsibility scheme on plastic beverage containers and beverage cartons in 2026. The scheme encourages citizens to return used containers for recycling to earn rebate, which will help significantly increase the recycling rate. Benefiting from the scheme, Baguio’s recycling volume is expected to be directly driven up, providing attractive returns for the Group’s long-term investments in recycling services and competitive barriers.The Government is actively developing the Northern Metropolis. Four new development areas include Kwu Tung North/ Fanling North, Hung Shui Kiu/Ha Tsuen, Yuen Long South, and San Tin Technopole are under construction. The Government has resumed more than 400 hectares of private land within these four new development areas, completed land levelling for 80 hectares, and is progressively handing over these lands to relevant departments for building road and railway infrastructure, public and private housing, schools, public markets, ecological conservation, as well as development of innovation and technology industry. The Group believes that this will bring opportunities for many of its core businesses.Looking forward, the Group will continue to increase the market share of its core businesses and proactively engage in expansion in Hong Kong and beyond. Meanwhile, in line with the development of the Group, it will actively explore potential mergers and acquisitions, joint ventures or new business projects to accelerate future business growth and deliver substantial and long-term returns to shareholders.For details of the Group's 2025 annual results announcement, please visit the following website: https://www.baguio.com.hk/en/investor/notices/About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental management solution providers. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, green products, horticulture & landscaping, and pest control. The Group delivers innovative environmental solutions using the latest technologies to serve a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city for a greener tomorrow. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Global Polo, the entertainment subsidiary of USPA Global, continues its historic relationship with ESPN to showcase the sport of polo, which has expanded its reach to millions of households worldwide. The landmark relationship includes legendary ESPN commentator Chris Fowler hosting the USPA Gold Cup® Final on Mar. 29 for the first time, and the U.S. Open Polo Championship® Final on Apr. 26 for the second year, at the USPA National Polo Center in Palm Beach County, Florida, alongside veteran broadcasters Kenny Rice and Polo Hall-of-Famer Adam Snow.Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco"I've had the privilege of covering some of the most iconic events in sports, and what continues to draw me back to the sport of polo is the unique partnership between the polo player and polo pony, as well as the speed and intensity of competition at the highest level," said Fowler. "Hosting both the USPA Gold Cup and the U.S. Open Polo Championship allows me to share the energy and uniqueness of this beautiful sport with a broader ESPN audience.""There's nothing quite like seeing these world-class athletes and their equine partners compete in such a fast-paced, strategic game," Fowler added.The USPA Gold Cup, first played in 1974, is the second most important tournament in American polo, right next to the U.S. Open Polo Championship, which was first played in 1904. This year's competition will feature 10 elite teams competing at the highest level of the sport from March 4 - 29. The prestigious U.S. Open Polo Championship, played April 1 - 26, is widely recognized as a showcase for many of the world's top players and equine athletes and remains one of the most prestigious polo tournaments globally. Both tournaments have been played back-to-back since they arrived in Palm Beach County, Florida, in 2004. These highly rated polo competitions take place on the U.S. Polo Assn. Stadium Field One at the USPA National Polo Center (NPC) in Wellington, Florida.Coverage of the USPA Gold Cup final in early April, followed by the U.S. Open Polo Championship final match in May, will be available on multiple ESPN platforms, including ESPN2. Check your local listings for specific airtimes."Our long-term relationship with ESPN continues to elevate the sport of polo, the U.S. Polo Assn. brand, and the global momentum behind it," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar global sport brand, U.S. Polo Assn. "Chris Fowler's return and expanded presence hosting both the USPA Gold Cup and the U.S. Open Polo Championship further strengthens the momentum and visibility of these world-class tournaments to a global audience.""Supported by ESPN, the sport of polo continues to garner interest from fans around the world," added Prince.Beyond live game coverage, ESPN platforms also feature new episodes of the two-time award-winning show, Breakaway: Presented by U.S. Polo Assn. produced by Global Polo. Viewers can follow exclusive behind-the-scenes coverage, player features, and championship highlights on Global Polo's YouTube channel, including special coverage tied to the USPA Gold Cup and the U.S. Open Polo Championship broadcasts."The United States Polo Association is delighted to see the continued growth of the sport through our relationship with ESPN," said Stewart Armstrong, Chairman of the United States Polo Association (USPA). "The USPA Gold Cup and the U.S. Open Polo Championship represent the highest level of competition at the USPA National Polo Center for the American season, and the increased visibility provided by ESPN underscores the athleticism, dedication, and tradition that define our sport."For the most up-to-date information and breaking news, sign up for the Polo Insider newsletter at globalpolo.com and visit uspolo.org.About ESPNESPN, the world's leading multiplatform sports entertainment brand, features seven U.S. television networks, the leading sports app, direct-to-consumer ESPN+, leading social and digital platforms, ESPN.com, ESPN Audio, endeavors on every continent around the world, and more.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About the United States Polo Association® (USPA)The United States Polo Association® is organized and exists for the purposes of promoting the game of polo; coordinating the activities of its member clubs and registered player members; arranging and supervising polo tournaments, competitions, and games; and providing rules, handicaps, and tournament conditions for those events. Its overarching goals are improving the sport and promoting the safety and welfare of its human and equine participants. Founded in 1890, the USPA is the largest voluntary sports organization in North America for the sport of polo. The USPA is currently made up of more than 200 member clubs and over 5,000 registered player members. It annually awards and oversees roughly 50 national tournaments hosted by its member clubs. For more information, please visit uspolo.org.For Additional Information, Contact:Shannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comStacey Kovalsky - VP, Global PR and CommunicationsPhone +001.954.673.1331 - E-mail: skovalsky@uspagl.comChristine Calcagno - Sr. Publicist, ESPN CommunicationsPhone +001.959.216.8036 - E-mail: christine.b.calcagno@espn.comSOURCE: USPA Global Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformation bridging study and preparation of Phase 2 clinical trial in 2025, of which the cost was less than large scale clinical studies in 2024. As at 31 December 2025, total funding available to use was approximately RMB351.5 million, representing a significant increase compared to RMB141.4 million as at 31 December 2024. During the year, the Group gained support from well-known institutional investors including Foresight, Fullgoal, and E Fund, completed two rounds of new share subscriptions under general mandate and successfully raised an aggregate amount of approximately HK$493.7 million in net proceeds. This drove net cash flows from financing activities for the Reporting Period to approximately RMB329.4 million, providing sufficient funding to support subsequent R&D and clinical advancement.SM17 Achieves Multiple BreakthroughsSM17 is a global first-in-class humanised monoclonal antibody (mAb) targeting the receptor for IL-25, which is capable of modulating Type II allergic reaction by targeting the receptor of a critical “alarmin” molecule interleukin-25 (IL-25). The compound has the potential for treating atopic dermatitis (AD), Inflammatory Bowel Disease (IBD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF).In the field of atopic dermatitis (AD), SM17 precisely targets upstream drivers of Type 2 immune responses by blocking IL-25, a key “alarmin” cytokine, thereby suppressing the inflammatory cascade at its source. While currently approved AD therapies, including biologics, can significantly improve Eczema Area and Severity Index (EASI) scores and patients’ quality of life, current drugs under development or on the market cannot simultaneously meet the clinical needs for rapid itch relief, skin lesion recovery, and good safety profiles, indicating substantial unmet market demand. SM17’s key innovation lies in its upstream modulation of the Th2 inflammatory cytokine pathway via IL-25 receptor inhibition, thereby suppressing multiple downstream pathogenic signaling pathways. Preclinical studies have demonstrated its potential for rapid itch relief, significant skin lesion recovery, and a favorable safety profile, directly addressing the key limitations of current therapies.In April 2025, SM17 achieved encouraging positive results in a Phase 1b study in China for the treatment of moderate to severe atopic dermatitis (AD): 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA0/1). These results significantly outperform IL-4/IL-13 monoclonal antibodies and demonstrate a significantly better safety and tolerability profile than Janus Kinase inhibitors (JAK inhibitors), making SM17 potentially the first-in-class and best-in-class therapeutics which can simultaneously achieve rapid onset of action on pruritic relief, skin healing with a good safety profile. Study results of SM17 were published in various leading international journals. Phase 2 clinical trial for AD is expected to be entered into as early as mid-2026.On 11 December 2025, an Investigational New Drug application (“IND”) for SM17 in the indication of IBD was filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (“NMPA”), and the IND was subsequently approved in February 2026. This IND submission represents an important step toward expanding SM17’s therapeutic scope beyond AD to IBD, including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), which are chronic, debilitating conditions with significant unmet medical needs. In October 2025, the first cohort of healthy subjects was dosed in a Phase 1 bridging clinical trial for the route of administration conversion in China. As of 31 December 2025, a total of 30 healthy subjects had been enrolled and our follow-up visits for all healthy subjects were completed in February 2026. This bridging study is expected to be completed by the second quarter of 2026. Data from this study will be leveraged to support the progression of the IBD indication directly to Phase 2 clinical development.Early-Stage Pipelines Drive Continuous Innovation GrowthIn terms of early-stage pipeline development, the Company continues to make steady progress. In June 2025, Its partner, Everest Medicines, has announced positive results from the Phase Ib/IIa clinical trial of EVER001 (SinoMab’s SN1011) for the treatment of primary membranous nephropathy (PMN), further enhancing the commercial value of the pipeline.At the same time, multiple early-stage R&D programs are progressing steadily. Anti-CGC antibody is an in-house developed, first-in-class humanised anti-γc antibody. Our in vitro assays suggested that our antibody could suppress inflammation and autoimmunity driven B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, alopecia areata and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration. We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.Bispecific antibody candidate is a novel, bispecific antibody targeting Receptor activator of the nuclear factor kappa-B ligand (RANKL) and sclerostin for bone-related indications. bsAb processes differential mechanisms of action tailored for the treatment of osteoporosis. Our in-house in vitro and in vivo studies demonstrated our candidate to have enhanced efficacy over market-approved antibodies such as Denosumab and Romosozumab. We are currently in the process of optimising CMC and testing toxicity in non-human primates and plan to submit our IND application by the first half of 2027 at the earliest.Expanding Strategic Partnerships and Gaining Strong Industry RecognitionsIn August 2025, the Company entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited (“SYSU-IAS”). Under the cooperation agreement, the Company enjoys direct access to SYSU-IAS’s comprehensive laboratory facilities and valuable data resources, as well as access to primate and non-primate animal studies supply resources, to accelerate the development of innovative drugs and promote the translation of scientific research into clinical applications worldwide. Furthermore, the Company is actively exploring the feasibility of using artificial intelligence (AI) technology for new target identification.In January 2026, the Company was invited to participate in the J.P. Morgan Healthcare Conference, where it shared its progress in the autoimmune field with multiple multinational pharmaceutical companies (MNCs) and investors.With the support of our strong R&D capabilities, extensive pipeline assets and refined operational management, we are thrilled to obtain renowned awards during the year, including the 2nd “New Quality Productive Forces Enterprise Award” jointly presented by the Greater Bay Area Family Office Association and the Hong Kong International Family Office Association, as well as the “Most Valuable Pharmaceutical Company Award” presented by Zhitong Finance.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, comments: "In 2025, we demonstrated the global competitiveness of our innovative pipeline with solid clinical data. The outstanding performance of SM17 in AD and its indication expansion to IBD signify our continuous transition from single-product R&D to the realisation of platform value. Looking ahead to 2026, the biopharmaceutical industry has been accelerating into the “Biotech 3.0 Era”, which is characterised by innovation-driven development, multidisciplinary integration, and intelligent processes across the entire supply chain. We are well-positioned to capture the historic opportunity of the rapid growth of out-licensing deals in China’s biopharmaceutical industry, continue to advance the clinical development of our core pipelines, and deepen our international partnership footprint. Relying on our solid cash reserves, full-spectrum capabilities across the industry chain and the principle of differentiated innovation, we strive to maximize the returns of shareholders in the long run and provide life-changing breakthrough therapies for patients.”About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeCitrus JiangWendy HuangPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 24, 2026 - (ACN Newswire via SeaPRwire.com) – Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the year ended December 31, 2025.Financial Highlights:- Revenue was RMB502.4 million for the year ended December 31, 2025, compared to RMB787.2 million for the year ended December 31, 2024.- Gross profit was RMB332.9 million for the year ended December 31, 2025, compared to RMB567.0 million for year ended December 31, 2024.- Net profit was RMB129.8 million for the year ended December 31, 2025, compared to RMB1,004.3 million for the year ended December 31, 2024.- Adjusted net profit (non-IFRS measure) was RMB137.9 million for the year ended December 31, 2025, compared to RMB221.4 million for the year ended December 31, 2025.Operation Highlights:- Gross transaction value amounted to RMB4.7 billion and the total number of orders reached 80.9 million for the year ended December 31, 2025.- Registered users reached over 415 million as of December 31, 2025.- The number of certified private car owners reached approximately 21 million as of December 31, 2025.Business OutlookMobility-related business 2025 marked a pivotal year as the Company transitioned from a single-focus carpooling platform toward a more integrated mobility and vehicle services platform. In 2025, the Company launched ride-hailing aggregation platform services to diversify service offerings. Such services are intended to complement the carpooling business by addressing additional mobility scenarios, including short-to-medium distance and immediate travel needs, in addition to the medium-to-long distance and pre-arranged travel scenarios typically served by carpooling. The Company also commenced used car trading referral services to expand business scope along the vehicle ownership lifecycle and enhance engagement within the Company’s car owner ecosystem. The Company believes carpooling in China is still at its early stage of development, with significant market demand yet to be fully released and the benefits of carpooling not fully recognized by the public. The Company will remain committed to innovation as the Company continues to develop unique competitive strengths and value around mobility scenarios to better serve the user base. In the future, the Company plans to further develop ride-hailing aggregation platform services and other mobility-related services and to continue to expand service offerings.For the full announcement of Dida for the annual results ended December 31, 2025, please visit:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf About Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides ride-hailing aggregation platform services to address additional mobility scenarios. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com